PubMed Health⌕ Search

Biomedical subjects

H Lode

Publications and source records attributed to H Lode.

At least 19 recordsLinked to original sources

[Pneumocystis jiroveci pneumonia in immunocompromised patients without AIDS -- a case series].

BACKGROUND AND OBJECTIVE: Patients with pneumonia resistant to treatment are a common problem in chest hospitals. Pneumocystis jiroveci (Pc) should always be considered as an opportunistic pathogen in case of potential, especially T cell-related immunodeficiency, even if AIDS is not obvious. We report on cases of Pneumocystis jiroveci pneumonia (PcP) (n = 1921) without associated AIDS in a chest hospital. PATIENTS AND METHODS: We assessed 1921 inpatients presenting with pneumonia during January 1 (st) 1996 and September 30 (th) 2005 in our hospital. Identification of the cases with PcP was based on discharge diagnosis as well as on our microbiological database (detection of Pc by immunofluorescence-test (IFT) and/or PCR). RESULTS: The diagnosis of PcP was made in 14 patients (11 males, 3 females) without associated AIDS. All patients were treated with immunosuppressive medication before admission. CD4 cell-counts were substantially decreased (CD4 cells < 200/microl) in 11 patients. To establish the diagnosis of PcP a Pc-PCR (using broncho-alveolar lavage (BAL) as the best material) was necessary in 8 patients, since the Pc-IFT proved positive only in 6 patients. Severe hypoxemia had to be managed by noninvasive ventilation in 3 patients, while another 4 patients had to be ventilated invasively. The mortality rate was 2 out of 14 patients. CONCLUSIONS: PcP is an important disease in the differential diagnosis of pneumonia and at the same time constitutes a severe pulmonary complication in immunodeficient patients. If immunodeficiency is suspected, a CD4 cell-count as well as bronchoscopy with BAL should be performed to diagnose PcP. As expected, Pc-PCR was superior to Pc-IFT and should therefore be used on a routine basis for diagnosing PcP.

Adult↗

[Serologic early diagnosis of pneumonia caused by Mycoplasma pneumoniae].

BACKGROUND AND OBJECTIVE: The definitive diagnosis of M. pneumoniae is encumbered by the lack of a rapid and cost-effective test of detection. The study aimed to determine if a single serological test within the first days of hospital admission may be relevant for the diagnosis of community-acquired pneumonia (CAP) caused by M. pneumoniae. PATIENTS AND METHODS: Patients with suspected of CAP were investigated for microbiological diagnosis based on respiratory samples (bronchoalveolar lavage, bronchial aspirate, sputum, throat rinse), blood culture and serology for detection of atypical organisms and viruses. Patients with M. pneumoniae antibody titers > or = 1:160 were further investigated by polymerase chain reaction (PCR) for detection of M. pneumoniae in respiratory samples. The group of CAP by M. pneumoniae (MP-CAP) included patients with serum titers > 1:160 of M. pneumoniae antibodies (based on a single antibody determination at admission). The control group (non-MP-CAP group) included patients with CAP by pathogens other than M. pneumoniae or with no definitive bacteriological diagnostic. RESULTS: Twenty adults with MP-CAP and 20 controls with non-MP-CAP were included. PCR was positive in 18/20 (90 %) of the MP-CAP group and negative in the 9/9 (100 %) investigated patients of the non-MP-CAP group. The duration of symptoms prior to hospital admission was rather long in both groups (mean 13.2 days in the MP-CAP group and 12,7 days in the non-MP-CAP group). The MP-CAP group was significantly younger (p = 0.002), had subsequently less associated comorbidities (p < 0.001) and less purulent sputum (p = 0.003) than the non-MP-CAP group. CONCLUSION: Single serology at admission with M. pneumoniae antibody titers > 1:160 may be useful for the diagnosis of CAP caused by M. pneumoniae in hospitalized patients with a long duration of symptoms (> 12 days).

Adult↗

[Diagnosis and therapy of aspiration pneumonia].

Aspiration pneumonia is an important and frequent complication following aspiration of infectious material from the oropharynx or stomach. Therefore the microbiological flora generally comprises a mixed spectrum of microbes including aerobic, microaerobic and anaerobic mircoorganisms. There are a number of risk factors for aspiration such as compromised consciousness or esophageal diseases. Aspiration pneumonia presents as a subacute or chronic disease. An endoscopic inspection of the bronchial system and a bacteriological evaluation should be performed in all patients. The principal therapeutic strategy for aspiration pneumonia is an antibiotic therapy. In uncomplicated cases a treatment for 7-10 days should be sufficient, but in case of complications like necrotizing pneumonia or lung abscess a prolonged administration (14-21 days, up to weeks or months) will be necessary. Recommended antibiotic regimens include clindamycin +/- cephalosporin, ampicillin/sulbactam and moxifloxacin.

Anti-Bacterial Agents↗

Characteristics and outcome of patients with active pulmonary tuberculosis requiring intensive care.

Severe tuberculosis (TB) requiring intensive care unit (ICU) care is rare but commonly known to be of markedly bad prognosis. The present study aimed to describe this condition and to determine the mortality rate and risk factors associated with mortality. Patients with confirmed TB admitted to ICU between 1990 and 2001 were retrospectively identified and enrolled. Clinical, radiological and bacteriological data at admission and during hospital stay were recorded. A multivariate analysis was performed to identify the predictive factors for mortality. A total of 58 TB patients (12 females, mean age 48 yrs) admitted to ICU were included. Mean Acute Physiology and Chronic Health Evaluation (APACHE) II score at admission was 13.1+/-5.6 and 22 of 58 (37.9%) patients required mechanical ventilation. The in-hospital mortality was 15 of 58 (25.9%); 13 (22.4%) patients died in the ICU. The mean survival of patients who died was 53.6 days (range 1-229), with 50% of the patients dying within the first 32 days. The factors independently associated with mortality were: acute renal failure, need for mechanical ventilation, chronic pancreatitis, sepsis, acute respiratory distress syndrome, and nosocomial pneumonia. These data indicate a high mortality of patients with tuberculosis requiring intensive care unit care and identifies new independently associated risk factors.

APACHE↗

Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study.

BACKGROUND: Piperacillin/tazobactam (P/T) with its broad spectrum of antibacterial activity is used widely for the treatment of moderate to severe polymicrobial nosocomial infections. PATIENTS AND METHODS: The efficacy and safety of P/T was compared with imipenem/cilastatin (I/C) in patients with established nosocomial pneumonia. This multicentre study took place from January 1999 to December 2001. Due to difficulties in recruiting sufficient patients it was terminated prematurely. In all, 221 patients were randomly assigned to either P/T at 4 g/0.5 g (n = 110) or I/C at 1 g/1 g (n = 111). Additional aminoglycoside therapy was mandatory if Pseudomonas aeruginosa was present. The ITT population (107 P/T and 110 I/C patients) was used for the analysis of efficacy. RESULTS: The clinical efficacy was equally good for the P/T and I/C groups; 71% [95% CI 61.3, 79.2] vs 77.3% [95% CI 68.1, 84.5] at the end of therapy, 66.4% [95% CI 56.5, 75] vs 70% [95% CI 60.4, 78.2] on day 3, a nd 59.8% [95% CI 49.9, 69] vs 66.4% [95% CI 56.6, 74.9] on day 14 after therapy, respectively. Proven or assumed bacterial eradication at the end of therapy was 45.8% (P/T) and 52.7% (I/C). Treatment-related adverse events (AE) were recorded in 30% of P/T patients and 25.2% I/C patients. There were ten serious treatment-related AEs in the P/T group and five in the I/C group. CONCLUSION: Although numbers were inadequate for full statistical evaluation, P/T and I/C were similarly effective in the treatment of severe nosocomially acquired pneumonia.

Adult↗

Mixed community-acquired pneumonia in hospitalised patients.

The role of mixed community-acquired pneumonia (CAP) is controversial. The aim of the present study was to determine the incidence, principal microbial patterns, clinical predictors and course of mixed CAP. The current study included 1,511 consecutive hospitalised patients with CAP. Of these, 610 (40%) patients had an established aetiology. One pathogen was demonstrated in 528 patients and 82 (13%) patients had mixed pneumonia. Cases including CAP, by a pyogenic bacteria and a complete paired serology for "atypicals", revealed that 82 (13%) patients had definite single pyogenic pneumonia and 28 patients (5%) had mixed pyogenic pneumonia. In patients with mixed CAP, Streptococcus pneumoniae was the most prevalent microorganism (44 out of 82; 54%). The most frequent combination was S. pneumoniae with Haemophilus influenzae (17 out of 82; 21%). Influenza virus A and S. pneumoniae (five out of 28; 18%) was the most frequent association in the mixed pyogenic pneumonia group. No clinical predictors for mixed pneumonias could be identified. Patients with mixed pyogenic pneumonia more frequently developed shock when compared with patients with single pyogenic pneumonia (18 versus 4%). In conclusion, mixed pneumonia occurs in >10% of cases with community-acquired pneumonia requiring hospitalisation.

Adolescent↗

[Fever of unknown origin in the 21st century: infectious diseases].

Fever of unknown origin (FUO) is a rare but important disease. The definition of FUO has not changed in the last 50 years. Classical FUO is defined by an illness of at least 3 weeks duration with fever greater than 38 masculine C, and no established diagnosis after 1 week of hospital investigation. The causes of FUO can be divided in four categories: infectious diseases, noninfectious inflammatory diseases, neoplasms, and others (miscellaneous). Recent studies have surprisingly shown that despite improved diagnostic procedures the percentage of patients with FUO, in which no diagnosis after intensive investigations in specialized centres can be found, has increased. However, finding the correct diagnosis in FUO is essential for these patients for psychological and vital reasons. Therefore and because of economic reasons patients with FUO should be investigated in specialized centres with a department for rheumatology and infectious diseases.

Aged↗

Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients.

The influence of steroids on the antibody response to a MF59-adjuvanted influenza vaccine in elderly COPD patients has not been studied previously. In the influenza season 2001/02 (October-February) elderly COPD patients were recruited at 14 doctor's offices and our 250-bed hospital. Patients were stratified into three groups according to current treatment regimen: (a) > 10 mg of prednisolone/day (SS); (b) inhaled steroids (IS); (c) no steroid treatment (control group, CG). All patients were vaccinated with the MF59-adjuvanted influenza vaccine. Antibodies against the influenza strains A/H1N1, A/H3N2, and B were measured at baseline, 4 and 24 weeks after vaccination by hemagglutination inhibition (HI) assay. One-hundred and sixty-two patients completed the study (CG n = 42; IS n = 87; SS n = 33). Mean age was 71.3 years (range 60-89). Twenty-one percent of all patients reported local reactions; no serious adverse events were observed. Four weeks after vaccination, mean geometric HI titres (GMT) for A/H1N1, A/H3N and B increased significantly in all groups (p < or = 0.05). After 24 weeks, GMTs to A/H1N1 and A/H3N2 returned to baseline, while GMTs to type B remained significantly higher than baseline in all groups. Significant differences between the groups as regards GMTs, seroconversion (56-89%) or seroprotection rates (64-93%) were not observed. Systemic steroids did not influence the antibody response towards the MF59-adjuvanted influenza vaccine. We found that the strains included in the vaccine showed varying long-term immunogenicity.

Adjuvants, Immunologic↗

HIV infection does not influence clinical outcomes in hospitalized patients with bacterial community-acquired pneumonia: results from the CAPO international cohort study.

In a case-control study, outcomes for 58 human immunodeficiency virus (HIV)-positive patients with community-acquired pneumonia (CAP) were compared with outcomes for 174 HIV-negative patients with CAP. No differences were found in the time to clinical stability, the length of hospitalization, and mortality. Clinical outcomes for hospitalized patients with CAP may not be influenced by HIV infection.

Adult↗

[Diagnosis of haemoptoe/haemoptysis].

Haemoptysis and haemoptoe mainly differ in the amount of expectorated blood. Causes of haemoptysis are diverse and include bronchitis, bronchiectasis, carcinoma, tuberculosis and other infectious pulmonary disease. Haemoptysis almost exclusively involves bronchial arteries, rarely vessels of the pulmonary-artery circuit. Asphyxia rather than the loss of blood ist life-threatening. 20 - 30 % of bronchopulmonary bleeding happens without any identifiable cause, about 90 % of haemoptyses are self-terminating. Chest X-ray is an integral part in each evaluation, as is bronchoscopy. Fiberoptic bronchoscopy is easily performed, although rigid bronchoscopy considerably extends the armamentarium of diagnostic and therapeutic measures. (Pulmangio-) chest CT scan as well as echocardiography and angiographic procedures provide extended diagnostic and therapeutic options. Surgery may be required in severe bleeding complications or during stable disease as a diagnostic approach.

Bronchoscopy↗

[Pneumococcal vaccination in obstructive lung diseases -- what can we expect?].

Many countries' guidelines recommend pneumococcal vaccination for patients suffering from obstructive airway disease. This paper reviews the literature as to immunogenicity and safety of this immunization. There is no evidence for a negative effect of pneumococcal vaccination on these patients. Only a few data exist on the preventive impact of pneumococcal vaccination as to exacerbations of obstructive airway diseases. Existing studies mostly took up this question as a side aspect. The effect in children and adults appears limited. On the other hand, the pneumococcal conjugate vaccine prevents life-threatening invasive infections in children younger than 5 years, and pneumococcal polysaccharide vaccine protects healthy adults against bacteriaemic pneumonia. Thus, pneumococcal vaccination of patients suffering from obstructive airway disease is recommendable.

Adolescent↗

Ciprofloxacin treatment failure in a patient with resistant Streptococcus pneumoniae infection following prior ciprofloxacin therapy.

Reported here is the case of a patient with underlying chronic obstructive pulmonary disease (COPD) in whom ciprofloxacin treatment of a lower respiratory tract infection failed subsequent to ciprofloxacin treatment of an exacerbation of COPD several weeks earlier. During the second course of ciprofloxacin therapy, the patient's condition continued to deteriorate, and she was admitted to the intensive care unit. Bilateral pneumonia was diagnosed. Streptococcus pneumoniae, serotype 11A, resistant to ciprofloxacin was isolated from the sputum. Sequencing revealed a S79F mutation in parC and there was evidence of an efflux pump. The patient improved rapidly after administration of azithromycin and ampicillin/sulbactam. This report of treatment failure due to ciprofloxacin-resistant Streptococcus pneumoniae shows that fluoroquinolones should be avoided when treating patients who have recently received this class of antibiotics.

Aged↗

Management of serious nosocomial bacterial infections: do current therapeutic options meet the need?

Hospital-acquired bacterial infections pose a formidable challenge for healthcare providers, as patients often need to be treated empirically, at least initially, although delay of appropriate initial antimicrobial therapy is known to increase morbidity significantly and to increase mortality among affected patients. This elevated risk is compounded by the presence of antibiotic-resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), extended-spectrum beta-lactamase-producing Enterobacteriaceae, Escherichia coli and Klebsiella pneumoniae. Prompt initiation of treatment with an appropriate antimicrobial agent that is active against both Gram-positive and Gram-negative organisms is prudent for patients with nosocomial infections. As the continued usefulness of vancomycin comes into question, the number of alternative agents that provide efficacy equal to that of vancomycin remains limited. The development of novel and effective alternative agents, such as tigecycline, is therefore important.

Anti-Bacterial Agents↗